HSCS | Heart Test Laboratories, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	3.17 - 4.20
52 Week Range	2.3600 - 18.50
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	131,832
Average Volume	348,304
Shares Outstanding	980,321
Market Cap	3,754,629
Sector	Healthcare
Industry	Medical - Devices
IPO Date	2022-06-16

Valuation
Profitability
Growth
Health
P/E Ratio	0.72
Forward P/E Ratio	N/A
EPS	5.35
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	15
Country	USA
Website	HSCS

Heart Test Laboratories, Inc., a medical technology company, provides cardiovascular diagnostic devices. The company offers MyoVista wavECG, a resting 12-lead electrocardiograph (ECG) to provide diagnostic information related to cardiac dysfunction, as well as conventional 12-lead resting ECG information. It serves clinics, doctor's offices, urgent care centers, and hospitals. The company was incorporated in 2007 and is headquartered in Southlake, Texas.

HSCS's peers: AEMD, BBLG, BJDX, BSGM, BVS, CODX, ECOR, HSDT, IINN, MYO, NAOV, NMTC, NURO, NUWE, QTRX, RSLS, TIVC, VERO, VVOS, TLIS, OPGN, INVO, TNON, MOTS

*Chart delayed

Analyzing fundamentals for HSCS we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is very weak. For more detailed analysis please see HSCS Fundamentals page.

Watching at HSCS technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on HSCS Technicals page.